TIDMDEST
RNS Number : 7558H
Destiny Pharma PLC
31 July 2023
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Publication of new data demonstrates significantly superior
efficacy of XF-73 compared to a leading topical antibiotic against
MRSA in skin infection models
Brighton, United Kingdom - 31 July 2023 - Destiny Pharma (AIM:
DEST), a clinical stage biotechnology company focused on the
development and commercialisation of novel medicines to prevent and
treat life threatening infections, today announces the publication
of new data in the journal Infection & Drug Resistance from a
study evaluating the potency of Destiny Pharma's antibacterial
drug, XF-73, against methicillin-resistant Staphylococcus aureus
(MRSA) in two, industry-standard, skin infection models and
comparing its efficacy against mupirocin, a leading topical
antibiotic.
The publication, entitled, " Efficacy of a Novel Antibacterial
Agent Exeporfinium Chloride, (XF--73), against Antibiotic-Resistant
Bacteria in Superficial Skin Infection Models" concluded that:
-- XF-73 dermal formulation was 100 times more effective at
killing MRSA (USA 300 strain) than the topical antibiotic
mupirocin, in two skin infection models
o Single doses of XF-73 and mupirocin reduced MRSA infection by
>3 log(10) CFU/mL (p<0.0001) and <1 log(10) , (p<0.05)
respectively, relative to control (no treatment)
-- XF-73 had significantly greater statistical efficacy than
mupirocin in both MRSA skin infection models, (p<0.0001)
-- Mupirocin had little or no impact on mupirocin resistant-MRSA
strains in the skin infection model, even following 2 doses,
whereas XF-73's potency was not impaired and was equally effective
against the mupirocin-resistant MRSA strains, maintaining a >3
log(10) reduction of this superbug
-- XF-73 further demonstrated its potency by achieving these
results at a concentration of 0.2% (w,w), compared to 2% (w,w)
marketed mupirocin ointment i.e. at 10 times less relative
concentration.
Destiny Pharma's partner, China Medical System Holdings Limited
(CMS) is developing the XF-73 dermal formulation as a treatment for
superficial skin infections through its relationship with Tianjin
Medical University.
The global acute bacterial skin and skin structure infections
market is estimated to be valued at US$ 3,466 million in 2022 and
is expected to exhibit a CAGR of 6.0% over the forecast period
(2022-2030).(1)
Destiny Pharma has cross-reference rights to data generated from
the programme and so retains the option to develop dermal XF-73
products for US, European, Japanese and other territories outside
those held by CMS (mainland China, Hong Kong Special Administrative
Region, Macao Special Administrative Region, Taiwan Region and
other certain Asian countries/regions).
This research project was partly funded through a GBP1.6m
collaboration between Destiny Pharma, Cardiff University, CMS and
Tianjin Medical University. The collaboration was established under
the UK-China antimicrobial resistance (AMR) grant fund set up by
Innovate UK and the Department of Health with the Chinese Ministry
of Science and Technology.
Dr Bill Love, Chief Scientific Officer of Destiny Pharma, said:
"This dataset is compelling and demonstrates clear and significant
advantages for XF-73 over one of the world's leading topical
antibiotics, mupirocin. It adds further impetus for the clinical
development of XF-73 to treat skin infections for CMS and Destiny
Pharma. It also provides a valuable additional read across of
comparative activity against MRSA and mupirocin-resistant strains
which are a growing cause of post-surgical infections and is
therefore supportive of our XF-73 nasal gel product."
Dr Debra Barker, Interim Chief Executive Officer of Destiny
Pharma, said: "The publication of these new data provides further
evidence of the superiority of XF-73 over the leading standard of
care and is highly relevant to our strategy to advance the product
across a range of indications. Working with CMS in this Innovate
UK-backed collaboration has many benefits, not least to our ability
to cross-reference these data, and we look forward to sharing
further progress."
Dr Phil Packer, Innovation Lead for AMR at Innovate UK, added:
"I am very excited to see the outputs from this productive
international collaborative project. It demonstrates great
commercial potential in the area of AMR where there is a dire need
for novel therapeutics such as XF-73."
1.
https://www.coherentmarketinsights.com/market-insight/acute-bacterial-skin-and-skin-structure-infections-absssi-market-1531
- END -
For further information, please contact:
Destiny Pharma plc
Debra Barker, Interim CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher
Ward
+44 (0) 20 7250 1446
Destiny@powerscourt-group.com
finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2 clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV(TM) ,
a novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
drug research projects.
For further information on the company, please visit
www.destinypharma.com
About XF-73
XF-73 is the lead drug candidate from Destiny Pharma's XF
platform, initially being developed for the prevention of
post-surgical staphylococcal infections, such as
methicillin-resistant Staphylococcus aureus (MRSA), which cause
significant complications and increased healthcare costs in the
hospital setting. XF -- 73 has been awarded both Qualified
Infectious Disease Product (QIDP) and Fast Track status by the US
FDA.
Dermal Infections
XF-73 is being developed as a new treatment for serious dermal
infections such as diabetic foot ulcer infections (DFUs) to target
a market which is estimated to be a $0.5 billion global sales
opportunity based on the incidence of such infections, the costs of
the associated medical care and a realistic product pricing of
XF-73 in this new market. Driven by the growing number of diabetics
and associated complications such as infected DFUs, this represents
a significant market opportunity for XF-73. It is estimated that
twenty-nine million people in US have a diagnosis of diabetes and
of these 13% have active DFUs.
As with all anti-infectives, AMR is also a concern within this
market. There is no dominant treatment for DFUs, and specialist
physicians are therefore working to find better treatment options,
including topical formulations. In addition, the target product
profile of XF-73 tested favourably with dermal clinicians looking
for better treatments for the smaller market for burns/wound
infections and venous leg ulcers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCNKDBPKBKDCON
(END) Dow Jones Newswires
July 31, 2023 07:01 ET (11:01 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Oct 2024 to Nov 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Nov 2023 to Nov 2024
